Bandingkan Harga & Kinerja Inti Bangun Sejahtera Tbk. (IBST) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Inti Bangun Sejahtera Tbk. dan Organon Pharma Indonesia Tbk.: Inti Bangun Sejahtera Tbk. diperdagangkan di Rp8.475 (kapitalisasi pasar 11,45 T), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Inti Bangun Sejahtera Tbk. jauh lebih besar — sekitar 109,7× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| IBST | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 11,45 T | 104,4 M |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Inti Bangun Sejahtera Tbk.
PT Inti Bangun Sejahtera Tbk formerly PT Inti Build Prosperous Tbk was established based on Notarial Deed No. 7 dated 28 April 2006 of Yulia, S.H., a notary in Jakarta.At first PT Inti Build Prosperous, Tbk provide signal amplification in buildings (in building system solution). Since the year 2009, PT Inti Build Prosperity has been providing telecommunication infrastructure such as telecommunications tower (tower providers) to meet the needs of mobile telecom operators in Indonesia. And at this time (July 2012) PT Inti Build Prosperity has 1.989 telecommunications tower.Currently, PT Inti Build Prosperous, Tbk provides services for several telecom operators, such as Smart Telecom, Indosat, Telkomsel, XL Axiata, Telkom Flexi, NTS, HCPT, Bakrie Telecom, through leasing tower spread throughout Indonesia.
Selengkapnya di halaman IBST →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
